Including a symposium exploring the effects of increased uptake of GLP-1 and GIP medications on the health insurance marketsAbout this Event
Nationwide, and in New Hampshire, healthcare costs and, consequently, health insurance premiums have exhibited a consistent and increasing upward trend. The ‘2025 Report’ will elucidate some of the key factors driving this trend. Key elements of the report include:
· Market structure and shifts in the previous year
· Service category-specific cost drivers, including prescription drugs and rebate value
· Comparative regional and national variations in healthcare premium, over time
· High-cost claimant graphics, by various group sizes
At the conclusion of presentation of the NHID 2025 report on healthcare premium and claim cost drivers, the NHID will host a symposium exploring the effects of increased uptake of GLP-1 and GIP medications on the health insurance markets, with a primary focus on cost and utilization. The panel discussion will feature experts with extensive knowledge of obesity medicine, as well as the economic impacts of these high-cost drugs on healthcare markets.
Discussion topics will include:
- Clinical utility and efficacy of GLP-1 and GIP medications
- How increased use of GLP-1 and GIP medications impacts insurance premiums
- Potential policy recommendations
Annual Hearing Presentation: Oliver Wyman Actuarial
Symposium Topic: GLP-1/GIP Medications: Cost and Utilization
Guest Speakers:
- Sarah Finn, MD, Section Chief, Obesity Medicine, The Walter and Carole Young Center for Digestive Health and Emma Dean, PhD, MS, Dartmouth Institute for Health Policy and Clinical Practice
- Sarah Emond, MPP, President and CEO of the Institute for Clinical and Economic Review
We urge you to engage in this important and informative discussion. Please submit questions in advance, via email, to .
Event Venue
NH Department of Health and Human Services, 129 Pleasant Street, Concord, United States
USD 0.00
